Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Oslo – page 29

527 clinical trials in Oslo, Norway across 9 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Oslo at a glance
527
clinical trials
  • Research sites9
Type of trial
Recruitment status
Quick filters

527 trials in Oslo

Open in trial search

Cardiac amyloidosis

Not recruiting

Study to Evaluate the Safety and Effectiveness of Vutrisiran in Patients with Transthyretin Amyloidosis and Heart Disease

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Vutrisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Carfilzomib, and Dexamethasone with Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Polish Myeloma Consortium

Chronic myeloid leukaemia

Not recruiting

Study on the Effectiveness and Safety of Ropeginterferon and Bosutinib for Patients with Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:St. Olavs Hospital HF

Squamous cell carcinoma of head and neck

Not recruiting

Study of Nimorazole Treatment Based on Hypoxia Profile in Head and Neck Cancer Patients Receiving Radiotherapy with Cisplatin

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Region Midtjylland

Colitis ulcerative

Not recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Colorectal cancer metastatic+1

Not recruiting

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer

Not recruiting

Study on Durvalumab and Stereotactic Body Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Vaestra Goetalandsregionen

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Hypoparathyroidism

Not recruiting

Study on the Safety and Effectiveness of TransCon PTH for Adults with Hypoparathyroidism

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Palopegteriparatide
  • Sponsor:Ascendis Pharma Bone Diseases A/S

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Primary adrenal insufficiency

Not recruiting

Study on Quality of Life in Patients Aged 16-80 with Primary Adrenal Insufficiency Using Hydrocortisone (Plenadren) and Cortisone

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Cortisone
  • Sponsor:Helse Bergen HF

Narcolepsy

Not recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Oslo

What the registry says about research in the country

01 Respiratory Medicine

Clinical trials focusing on pulmonary conditions and respiratory health, including studies on idiopathic pulmonary fibrosis and respiratory syncytial virus prevention in children.

  • IPF Treatment Evaluation
  • RSV Prevention Studies
  • Chronic Wet Cough Research

Innovative therapies being tested to improve lung function and patient outcomes.

02 Cardiovascular Research

Studies examining heart conditions and vascular health, with particular focus on heart failure and cardiovascular disease prevention.

  • Heart Failure Imaging Studies
  • Cardiovascular Disease Prevention
  • Hypovolemia Management

Advanced imaging techniques and therapeutic interventions being evaluated for cardiac conditions.

03 Oncology Studies

Comprehensive research into various cancer treatments, including trials for gastric, esophageal, and rare cancers.

  • Advanced Solid Tumors
  • Targeted Cancer Therapies
  • Multiple Myeloma Treatment

Novel therapeutic approaches combining immunotherapy with conventional treatments.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.